Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Winters

Podiatrist, Foot & Ankle Surgery Carmel, IN Doctor of Podiatric Medicine

NPI 1275628398 CMS profile 12099

12188B N Meridian St Ste 330, Carmel, IN 46032

Open in the dashboard

General payments

$152,052

299 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$185,727

2 holdings reported · through program year 2025

Research they led as principal investigator

$6,000 paid to institutions, not to them · program year 2021

Through program year 2025, Christopher Winters of Carmel, IN is reported in the CMS Open Payments database as having received $152,052 across 299 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,000 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $185,727 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,658 57
2024 General $56,738 71
2023 General $25,570 44
2022 General $12,975 15
2021 General $7,601 25
2020 General $9,830 31
2019 General $14,681 56
2022 Ownership $183,747 1
2019 Ownership $1,980 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Winters
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Christopher Winters were reported at $24,658. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Christopher Winters Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $14,681 $389 $118–$1,406 $163
2020 $9,830 $191 $62–$691 $114
2021 $7,601 $329 $104–$1,341 $132
2022 $12,975 $419 $125–$1,611 $149
2023 $25,570 $377 $128–$1,164 $160
2024 $56,738 $394 $134–$1,168 $164
2025 $24,658 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kerecis Limited $122,270 81 payments
  2. Sanara MedTech Inc. $11,524 11 payments
  3. Medline Industries, Inc. $10,239 31 payments
  4. ConvaTec Inc. $2,428 15 payments
  5. Smith+Nephew, Inc. $1,219 58 payments
  6. Organogenesis Inc. $699 15 payments
  7. Urgo Medical North America, LLC $528 3 payments
  8. Paratek Pharmaceuticals, Inc. $416 18 payments
  9. Stryker Corporation $414 5 payments
  10. PolyNovo North America LLC $312 6 payments
  11. Other $2,003 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $62,700 10 payments
  2. Travel and Lodging $22,510 32 payments
  3. Consulting Fee $21,192 9 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,750 8 payments
  5. Food and Beverage $14,401 234 payments
  6. Education $7,900 2 payments
  7. Honoraria $6,600 4 payments
Products named General payments · program years 2019–2025
  1. Kerecis Omega3 SurgiClose Wound Care $79,534 35 payments
  2. Kerecis Omega3 Marigen Wound Care $55,602 24 payments
  3. Kerecis Omega3 Marigen Wound Care $42,718 20 payments
  4. Kerecis Omega3 Marigen Wound Care $42,718 20 payments
  5. Kerecis Omega3 Marigen Wound Care $42,718 20 payments
  6. Kerecis Omega3 GraftGuide $36,817 15 payments
  7. Kerecis Omega3 SurgiClose Wound Care $23,932 11 payments
  8. Kerecis Omega3 SurgiClose Wound Care $23,932 11 payments
  9. Kerecis Omega3 Marigen Wound Care $23,932 11 payments
  10. Kerecis SurgiClose $22,810 31 payments
  11. Other $180,971 415 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

242

Median for Podiatry: 160

Drug cost

$29,779

Median for Podiatry: $2,368

Branded share of claims

36.8%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 24 $23,386
Santyl Collagenase Clostridium Hist. Brand 15 $4,401
Doxycycline Hyclate Generic 79 $918
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 35 $437
Ciprofloxacin Hcl Generic 24 $251
Gabapentin Generic 26 $209
Terbinafine Hcl Generic 11 $84
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $71
Amoxicillin Generic 13 $23

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$224,807

Of which drugs: $72,749

Medicare patients

410

Average age 76

Services billed

2,968

195 women, 215 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Arthritis 51%
Chronic kidney disease 44%
Ischemic heart disease 43%
Atrial fibrillation 30%
Depression 30%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $37
$37 — —
Cabtreo
  • Ortho Dermatologics, a division of Bausch Health US, LLC $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

299 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record